仑伐替尼联合依维莫司一线治疗晚期非透明细胞肾细胞癌的单臂多中心2期研究
这项开放标签、单臂、多中心2期研究纳入31例未接受过系统治疗的晚期非透明细胞肾细胞癌患者,给予仑伐替尼18 mg联合依维莫司5 mg每日一次口服。结果显示客观缓解率为26%(95%CI 12-45),中位无进展生存期9.2个月,中位总生存期15.6个月,安全性特征与已知联合方案一致。
要点
- 仑伐替尼联合依维莫司一线治疗晚期nccRCC的ORR为26%。
- 中位PFS为9.2个月,中位OS为15.6个月。
- 常见不良事件为疲乏、腹泻、食欲下降、恶心和呕吐。
核心结论
- 仑伐替尼联合依维莫司在晚期非透明细胞肾细胞癌中显示出有希望的抗肿瘤活性,ORR为26%。
- 安全性特征与该联合方案的已知特征一致。
研究设计与样本
- 开放标签、单臂、多中心2期研究。
- 纳入31例不可切除晚期或转移性非透明细胞肾细胞癌患者,既往未接受过针对晚期疾病的抗癌治疗。
- 干预为仑伐替尼18 mg联合依维莫司5 mg每日一次口服。
主要发现
- 最佳总体疗效为部分缓解,共8例(乳头状3例、嫌色细胞4例、未分类1例),总体ORR为26%(95%CI 12-45)。
- 中位无进展生存期为9.2个月(95%CI 5.5-不可估计),中位总生存期为15.6个月(95%CI 9.2-不可估计)。
- 最常见治疗中出现的不良事件为疲乏(71%)、腹泻(58%)、食欲下降(55%)、恶心(55%)和呕吐(52%)。
关键数值与推荐
- 主要终点为研究者根据RECIST 1.1评估的客观缓解率。
- ORR的95%CI采用双侧Clopper-Pearson法计算。
- 中位PFS和OS采用Kaplan-Meier法估计,95%CI采用广义Brookmeyer-Crowley法估计。
临床怎么用
- 对于未经系统治疗的晚期非透明细胞肾细胞癌患者,仑伐替尼联合依维莫司可作为候选一线治疗选择。
- 治疗期间需关注疲乏、腹泻、食欲下降、恶心和呕吐等常见不良事件。
局限性
- 样本量小。
- 单臂设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Non-clear cell renal cell carcinoma (nccRCC) accounts for ≤20% of RCC cases. Lenvatinib (a multitargeted tyrosine kinase inhibitor) in combination with everolimus (an mTOR inhibitor) is approved for the treatment of advanced RCC after one prior antiangiogenic therapy. OBJECTIVE: To determine the safety and efficacy of lenvatinib plus everolimus as a first-line treatment for patients with advanced nccRCC. DESIGN, SETTING, AND PARTICIPANTS: This open-label, single-arm, multicenter, phase 2 study enrolled patients with unresectable advanced or metastatic nccRCC and no prior anticancer therapy for advanced disease. INTERVENTION: Lenvatinib (18 mg) plus everolimus (5 mg) orally once daily. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint was the objective response rate (ORR) as assessed by investigators according to Response Evaluation Criteria in Solid Tumors version 1.1. Secondary endpoints included progression-free survival (PFS), overall survival (OS), and safety assessments. The 95% confidence intervals (CIs) for ORRs were calculated using the two-sided Clopper-Pearson method. Median PFS and median OS were estimated using the Kaplan-Meier product-limit method and their 95% CIs were estimated via a generalized Brookmeyer and Crowley method. RESULTS AND LIMITATIONS: The study (start date: February 20, 2017) enrolled 31 patients with nccRCC (papillary, n = 20; chromophobe, n = 9; unclassified, n = 2). At the data cutoff date (July 17, 2019), the best overall response was a partial response (eight patients: papillary, n = 3; chromophobe, n = 4; unclassified, n = 1) for an overall ORR of 26% (95% CI 12-45). Median PFS was 9.2 mo (95% CI 5.5-not estimable), and median OS was 15.6 mo (95% CI 9.2-not estimable). The most common treatment-emergent adverse events were fatigue (71%), diarrhea (58%), decreased appetite (55%), nausea (55%), and vomiting (52%). Limitations include the small sample size and single-arm design. CONCLUSIONS: Lenvatinib plus everolimus showed promising anticancer activity in patients with advanced nccRCC with an ORR of 26% and is worthy of further study. The safety profile was consistent with the established profile of the study-drug combination. PATIENT SUMMARY: We examined the combination of lenvatinib plus everolimus as the first therapy for 31 patients who had advanced nccRCC. We found that this treatment seemed effective, because most patients had a decrease in tumor size and manageable treatment-related side effects. CLINICAL REGISTRATION: This trial is registered at ClinicalTrials.Gov as NCT02915783.
引用
- Hutson TE, Michaelson MD, Kuzel TM, et al. A Single-arm, Multicenter, Phase 2 Study of Lenvatinib Plus Everolimus in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma. Eur Urol. 2021. PMID: 33867192. doi:10.1016/j.eururo.2021.03.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。